Vadim Tarasov, director of the Institute for Translational Medicine and Biotechnology, according to Sputnik on July 12, 2020, successfully completed clinical trials of the world’s first coronavirus vaccine in volunteers at the First Moscow State Medical University, Sechenov.
“Sechenov University has successfully completed volunteer testing of the world’s first coronavirus vaccine,” said Tarasov.
Tarasov added that the first group of volunteers would be discharged on July 15, 2020, followed by the second group on July 20.
The university began clinical trials of the vaccine produced by Russia’s Gamalei Institute of Epidemiology and Microbiology on June 18, 2020, he said. Sputnik News.
The Russian candidate vaccine COVID-19 was developed by the same government laboratories that developed what is said to be ‘an effective vaccine against the Ebola virus, as well as a vaccine against the MERS virus,’ reported the Washington Post.
From 2015-2019, the National Research Institute for Epidemiology and Microbiology in Gamaleya actively focused on the work of vaccines related to research and development, which has supposedly been used for the new coronavirus vaccine.
According to Alexander Lukashev, director of the Sechenov University, the objective of this stage of the study was to show the safety of the vaccine for human health, which was carried out successfully.
“The safety of the vaccine is confirmed. It corresponds to the safety of vaccines that are currently on the market, “Lukashev told Sputnik.
The development plan for the additional vaccine is already being determined by the developer’s strategy, including the complexity of the epidemiological situation with the virus and the possibility of increasing production, Lukashev added.
“Sechenov University, in a pandemic situation, acted not only as an educational institution but also as a scientific and technological research center, which can participate in the creation of products as important and complex as drugs …”
“We are working with this vaccine, starting with preclinical studies and protocol development, and clinical trials are currently underway,” Tarasov said.
The Russian vaccine COVID-19 is reported to use a weakened virus to release small parts of a pathogen and stimulate an immune response. And it is a vector vaccine based on adenovirus DNA, in which the coronavirus SARS-CoV-2 gene is integrated.
Adenovirus is used as a “container” to deliver the coronavirus gene to cells, starting synthesis of the envelope proteins of the new coronavirus, “introducing” the immune system to a potential enemy.
Kirill Dmitriev, educated at Stanford and Harvard University, CEO of the Russian Direct Investment Fund (RDIF), commented: “The Russian research base for vaccine development is one of the best in the world, and we hope that the Russian vaccine to be one of the first in the world ready to be used, “TrialSiteNews reported.
Following the completion of clinical trials of the vaccine, RDIF and Alium are ready to launch mass production for the fastest possible vaccination of Russian citizens.
Precision vaccines published news about the development of vaccines against coronavirus.
